TWI718121B - 抗甲狀腺素運送蛋白抗體 - Google Patents

抗甲狀腺素運送蛋白抗體 Download PDF

Info

Publication number
TWI718121B
TWI718121B TW105102534A TW105102534A TWI718121B TW I718121 B TWI718121 B TW I718121B TW 105102534 A TW105102534 A TW 105102534A TW 105102534 A TW105102534 A TW 105102534A TW I718121 B TWI718121 B TW I718121B
Authority
TW
Taiwan
Prior art keywords
antibody
ttr
seq
variable region
heavy chain
Prior art date
Application number
TW105102534A
Other languages
English (en)
Chinese (zh)
Other versions
TW201636372A (zh
Inventor
班傑明 安德魯 雪弗
阿維吉特 查克拉波提
傑佛瑞 Ｎ 檜垣
Original Assignee
愛爾蘭商普羅佘納生物科技有限公司
大學健康網絡
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 愛爾蘭商普羅佘納生物科技有限公司, 大學健康網絡 filed Critical 愛爾蘭商普羅佘納生物科技有限公司
Publication of TW201636372A publication Critical patent/TW201636372A/zh
Application granted granted Critical
Publication of TWI718121B publication Critical patent/TWI718121B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW105102534A 2015-01-28 2016-01-27 抗甲狀腺素運送蛋白抗體 TWI718121B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562109001P 2015-01-28 2015-01-28
US62/109,001 2015-01-28
US201562266557P 2015-12-11 2015-12-11
US62/266,557 2015-12-11

Publications (2)

Publication Number Publication Date
TW201636372A TW201636372A (zh) 2016-10-16
TWI718121B true TWI718121B (zh) 2021-02-11

Family

ID=55361912

Family Applications (2)

Application Number Title Priority Date Filing Date
TW105102534A TWI718121B (zh) 2015-01-28 2016-01-27 抗甲狀腺素運送蛋白抗體
TW110100084A TWI781507B (zh) 2015-01-28 2016-01-27 抗甲狀腺素運送蛋白抗體

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110100084A TWI781507B (zh) 2015-01-28 2016-01-27 抗甲狀腺素運送蛋白抗體

Country Status (19)

Country Link
US (1) US20160257736A1 (cg-RX-API-DMAC7.html)
EP (1) EP3250594B1 (cg-RX-API-DMAC7.html)
JP (2) JP6875280B2 (cg-RX-API-DMAC7.html)
KR (1) KR102619359B1 (cg-RX-API-DMAC7.html)
CN (1) CN107428822B (cg-RX-API-DMAC7.html)
AU (1) AU2016210887B2 (cg-RX-API-DMAC7.html)
CA (1) CA2974911A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017008469A2 (cg-RX-API-DMAC7.html)
CU (1) CU24532B1 (cg-RX-API-DMAC7.html)
EA (1) EA036048B1 (cg-RX-API-DMAC7.html)
ES (1) ES2905311T3 (cg-RX-API-DMAC7.html)
MX (1) MX391789B (cg-RX-API-DMAC7.html)
MY (1) MY193674A (cg-RX-API-DMAC7.html)
PE (1) PE20180200A1 (cg-RX-API-DMAC7.html)
SA (1) SA517381991B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201706125QA (cg-RX-API-DMAC7.html)
TW (2) TWI718121B (cg-RX-API-DMAC7.html)
WO (1) WO2016120809A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201705662B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI718121B (zh) * 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007924A2 (en) * 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478715A2 (en) * 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007922A2 (en) * 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
EP3691626A4 (en) * 2017-10-06 2021-06-30 Prothena Biosciences Limited METHODS OF DETECTION OF TRANSTHYRETINE
AU2018345806A1 (en) * 2017-10-06 2020-03-12 Novo Nordisk A/S Anti-transthyretin antibodies
PH12020550694A1 (en) 2017-11-29 2021-04-12 Prothena Biosciences Ltd Lyophilized formulation of a monoclonal antibody against transthyretin
WO2020247452A1 (en) * 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用
TW202525341A (zh) 2023-12-15 2025-07-01 丹麥商諾佛 儂迪克股份有限公司 穩定的液體調配物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140056904A1 (en) * 2012-08-24 2014-02-27 University Health Network Antibodies to TTR and Methods of Use

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CN100489892C (zh) 1999-02-05 2009-05-20 三星电子株式会社 恢复描述图像的纹理特征的图像纹理描述符的方法及装置
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
AU2002361886A1 (en) 2001-12-28 2003-07-24 Abgenix, Inc. Antibodies against the muc18 antigen
AU2003302689B2 (en) 2002-11-29 2009-02-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel neomycin phosphotransferase genes and method for the selection of high-producing recombinant cells
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
EP1820022B1 (en) 2004-11-10 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
WO2007124345A2 (en) 2006-04-21 2007-11-01 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
WO2008107388A1 (en) 2007-03-02 2008-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improvement of protein production
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
WO2010030203A1 (en) * 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
US9790269B2 (en) * 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140056904A1 (en) * 2012-08-24 2014-02-27 University Health Network Antibodies to TTR and Methods of Use

Also Published As

Publication number Publication date
CO2017008469A2 (es) 2018-01-16
MX2017009804A (es) 2018-08-15
CA2974911A1 (en) 2016-08-04
BR112017016324A2 (pt) 2018-03-27
AU2016210887B2 (en) 2021-11-04
WO2016120809A1 (en) 2016-08-04
EP3250594A1 (en) 2017-12-06
JP6875280B2 (ja) 2021-05-26
SA517381991B1 (ar) 2021-12-13
MY193674A (en) 2022-10-24
US20160257736A1 (en) 2016-09-08
EP3250594B1 (en) 2021-11-17
PE20180200A1 (es) 2018-01-31
SG11201706125QA (en) 2017-08-30
TWI781507B (zh) 2022-10-21
TW202118782A (zh) 2021-05-16
JP7219928B2 (ja) 2023-02-09
JP2018509889A (ja) 2018-04-12
CU20170096A7 (es) 2018-03-13
KR20170120607A (ko) 2017-10-31
AU2016210887A1 (en) 2017-08-10
EA201791711A1 (ru) 2017-11-30
EA036048B1 (ru) 2020-09-18
ZA201705662B (en) 2018-08-29
KR102619359B1 (ko) 2024-01-02
CN107428822B (zh) 2021-11-23
CN107428822A (zh) 2017-12-01
TW201636372A (zh) 2016-10-16
MX391789B (es) 2025-03-21
JP2021129562A (ja) 2021-09-09
ES2905311T3 (es) 2022-04-07
CU24532B1 (es) 2021-07-02

Similar Documents

Publication Publication Date Title
TWI711631B (zh) 抗甲狀腺素運送蛋白抗體
TWI718122B (zh) 抗甲狀腺素運送蛋白抗體
TWI718121B (zh) 抗甲狀腺素運送蛋白抗體
JP7016470B2 (ja) 抗トランスサイレチン抗体
US11629185B2 (en) Anti-transthyretin antibodies
JP2019530428A (ja) 抗トランスサイレチン抗体
US10633433B2 (en) Anti-transthyretin antibodies
HK1240249B (en) Anti-transthyretin antibodies
HK1240247A1 (en) Anti‐transthyretin antibodies
HK1240247B (en) Anti‐transthyretin antibodies
BR112017016324B1 (pt) Anticorpo humanizado, composição farmacêutica, ácido nucleico e uso de um regime efetivo e de uma quantidade efetiva do anticorpo humanizado

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees